Interactions of solid lipid nanoparticles with model membranes and leukocytes studied by EPR

被引:31
作者
Kristl, J
Volk, B
Ahlin, P
Gombac, K
Sentjurc, M
机构
[1] Univ Ljubljana, Fac Pharm, Ljubljana 1000, Slovenia
[2] Jozef Stefan Inst, Ljubljana 1000, Slovenia
关键词
solid lipid nanoparticles; interactions; liposomes; leukocytes; electron paramagnetic resonance (EPR);
D O I
10.1016/S0378-5173(03)00070-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Solid lipid nanoparticles (SLN) are colloidal systems which have been proposed for several administration routes. Only limited data are available about the mechanism and rate of interaction of SLN with cells and tissues. The aim of our study was to investigate interactions of SLN with model membranes (liposomes) and cells (leukocytes). SLN dispersions composed of glyceryl tripalmitate, phosphatidylcholine, water, and poloxamer 188 or Tween 20 were prepared by the melt-emulsification process. Spin-labeled phosphatidylcholine (PC(10,3)) and the methylester of doxyl palmitic acid (MeFASL(10,3)) were incorporated into SLN as spin probes (SPs) in order to determine the rate and mechanism of cell interaction by electron paramagnetic resonance (EPR) spectroscopy. Our results indicate that the exchange of SP between SLN and liposomes is much faster for MeFASL(10,3) than for PC(10,3), probably due to the smaller size of the former. In contrast to liposomes, in leukocytes no significant difference in the transfer rates of the two SP was observed after incubation, suggesting that there is an uptake of SLN to leukocytes (endocytosis) although simultaneous SP diffusion is not excluded. The interaction of SLN with leukocytes appears to depend significantly on the stabilizer used. Transfer of PC(10,3) from SLN coated with poloxamer 188 is much faster than from SLN coated with Tween 20. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 16 条
[1]  
Ahlin P, 2000, STP PHARMA SCI, V10, P125
[2]   Influence of spin probe structure on its distribution in SLN dispersions [J].
Ahlin, P ;
Kristl, J ;
Sentjurc, M ;
Strancar, J ;
Pecar, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) :241-244
[3]  
Ahlin P, 1998, ACTA PHARM, V48, P257
[4]  
Alberts B., 1994, MOL BIOL CELL
[5]   Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats [J].
Bargoni, A ;
Cavalli, R ;
Caputo, O ;
Fundarò, A ;
Gasco, MR ;
Zara, GP .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :745-750
[6]   Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles [J].
Bocca, C ;
Caputo, O ;
Cavalli, RB ;
Gabriel, L ;
Miglietta, A ;
Gasco, MR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 175 (02) :185-193
[7]   Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin:: Pharmacokinetics and tissue distribution after i.v. administration to rats [J].
Fundarò, A ;
Cavalli, R ;
Bargoni, A ;
Vighetto, D ;
Zara, GP ;
Gasco, MR .
PHARMACOLOGICAL RESEARCH, 2000, 42 (04) :337-343
[8]   Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel [J].
Miglietta, A ;
Cavalli, R ;
Bocca, C ;
Gabriel, L ;
Gasco, MR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 210 (1-2) :61-67
[9]   Enhanced transport of nanoparticle associated drugs through natural and artificial membranes -: a general phenomenon? [J].
Müller, B ;
Kreuter, J .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 178 (01) :23-32
[10]   Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant [J].
Muller, RH ;
Ruhl, D ;
Runge, S ;
SchulzeForster, K ;
Mehnert, W .
PHARMACEUTICAL RESEARCH, 1997, 14 (04) :458-462